Loading clinical trials...

Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization | Clinical Trials | Clareo Health

COMPLETEDNA

Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization

NCT03475888•Erasmus Medical Center

View on ClinicalTrials.gov

Summary

A chronic total occlusion (CTO) is common in patients with coronary artery disease. CTO recanalization has been shown to improve survival in comparison to failed CTO recanalization. Whether this is related to ventricular arrhythmias (VA) is unknown. The purpose of this pilot study is to evaluate the incidence of VA after successful CTO recanalization and in those with failed CTO recanalization or untreated CTO. Patients will be monitored using an insertable cardiac monitor.

Detailed Description

Rationale: Successful chronic total occlusion (CTO) recanalization has been associated with improved long-term survival. Furthermore, CTO is an independent predictor for the occurrence of ventricular arrhythmias (VA) in patients with ischemic cardiomyopathy and implantable cardioverter defibrillators (ICDs). One may speculate that a successful CTO recanalization may provide electrical stability. However, no data are available on the incidence of sustained VA in this patient population. Objective: The objective of the present pilot study is to assess the incidence of sustained VA in 2 CTO groups: patients with successful percutaneous CTO recanalization (group A), patients with failed percutaneous CTO recanalization or untreated CTO (group B). Study design: Pilot study of patients with CTO. Study population: A total of 90 patients will be enrolled with a maximum of 45 patients in each arm. Intervention: A Medtronic Reveal LINQ™ Insertable cardiac monitor (ICM) will be implanted in every patient to continuously monitor heart rhythm during the follow-up period. Main study parameters/endpoints: To assess the incidence of VA defined as sustained ventricular tachycardia \>30 s or ventricular fibrillation.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Presence of CTO defined as complete obstruction of the vessel with Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 and an estimated duration of ≥3 months, and one of the following:
•1. A successful percutaneous CTO recanalization for stable angina within the previous 6 months. A successful CTO recanalization is defined as a final TIMI flow grade ≥2 and a residual stenosis ≤30% after stent implantation.
•2. A failed percutaneous CTO recanalization for stable angina within the previous 6 months. A failed CTO recanalization is defined as not fulfilling the criteria for successful CTO recanalization.
•3. Untreated CTO diagnosed in the previous 6 months.
•2. Age ≥18 years.
•3. Written informed consent.
•4. Patient agrees to the follow-up including the implantation of the ICM.

Exclusion Criteria

•1. Patients who are potential candidates for an ICD according to the 2015 ESC guidelines.
•2. Patients who have a cardiac implantable electrical device (CIED) (e.g., pacemaker, ICD).
•3. Patient has reduced immune function or is otherwise at high risk for infection.
•4. Patient has had a recent (within 30 days) or otherwise unresolved infection.
•5. Known pregnancy at time of inclusion.
•6. Patient has severe co-morbidity that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than one year).

Locations (2)

VUMC

Amsterdam, Netherlands

Erasmus Medical Center

Rotterdam, Netherlands

Key Dates

Start Date

September 28, 2018

Primary Completion Date

December 12, 2022

Completion Date

December 12, 2022

Last Updated

February 20, 2024

Enrollment

ACTUAL participants

Conditions

Chronic Total Occlusion of Coronary Artery

Interventions

Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)

DEVICE

Coronary Crossing System in Patients With Coronary Chronic Total Occlusions

NCT05813704

Chronic Total Occlusion of Coronary Artery

View study

RECRUITINGNA

To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.

NCT04944615

Chronic Total Occlusion of Coronary Artery

View study

COMPLETEDNA

Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization

Inclusion Criteria

Exclusion Criteria

Coronary Crossing System in Patients With Coronary Chronic Total Occlusions

To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.

Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention

Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography Angiography

The BLIMP Balloon in Coronary Interventions

Antegrade and Retrograde Dissection and Re-entry Approach for CTO